IBS Test Validated for Use with Finger Stick Whole Blood Collection Technology
The inFoods IBS test has been validated for use with finger stick blood samples simplifying collection and facilitating access to the test.
Category: Specimen Collection & Handling
Specimen Collection & Handling
Latest
Specimen Collection & Handling
Latest
Saliva Testing Shows Promise for Patients with Psychiatric Disorders
Research points to saliva testing as a potential alternative to blood sampling for patients with bipolar disorder, schizophrenia, and depression.
Specimen Collection & Handling
Latest
Renal Cell Carcinoma Liquid Biopsy Trial Underway
The AUR87A trial will involve 16 hospitals across Europe and the United States, making it the largest-ever prospective multicenter study of a diagnostic for the detection of recurrence after surgery in clear cell renal cell carcinoma.
ClearLight to Develop and Commercialize 3-D Tissue-Clearing Technology
ClearLight will combine the new Crystal technology with its Clarity automated lipid-clearing platform.
Read MoreElypta Announces Study of Liquid Biopsy for Kidney Cancer Diagnosis
The study will evaluate the utility of Elypta’s liquid biopsy platform for the early detection of recurrence in renal cell carcinoma patients after surgery.
Read More
Liquid Biopsy Technology Detects Microsatellite Instability in Circulating Tumor DNA
The study results point to the value of liquid biopsies as a noninvasive approach to genotyping and monitoring in patients diagnosed with advanced forms of cancer.
Read More
Hybrid Tubes Improve Tissue Sample Storage
Uniform tissue storage products enable biobanks to standardize and automate the handling and storage of tissue samples in the same way as liquid samples.
Read More
Menarini Silicon Biosystems Launches VRNxT Volume-Reduction Instrument
Automated volume reduction increases precision and accuracy in rare-cell workflows.
Read MoreSysmex Obtains First Liquid Biopsy Approval in Japan
The test reduces the need for invasive tissue biopsies.
Read More
New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics
The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.
Read More
Liquid Biopsy for Prostate Cancer Granted NY Licensure
The test helps clinicians to determine whether a patient with metastatic castration-resistant prostate cancer will benefit most from taxane chemotherapy or androgen-directed therapeutics.
Read More
Liquid Biopsy Test from Personal Genome Diagnostics Receives CE Mark
Certification of the Elio Plasma Resolve liquid biopsy panel will make available a local, noninvasive, next-generation sequencing solution in Europe.
Read More
New Assay is a Potential Alternative to Bone Marrow Biopsy
The liquid biopsy may enable clinical researchers to better understand tumor biology, particularly in early-stage disease.
Read More
Bio-Rad Releases First FDA-Cleared Liquid Biopsy Test for Chronic Myeloid Leukemia
Using the kit, clinicians can accurately and reproducibly monitor residual disease in patients with chronic myeloid leukemia, even at low levels.
Read More
Precipio and PerkinElmer Collaborate to Provide Liquid Biopsy Solutions
Together, Precipio and PerkinElmer can provide a simple, reliable, automated cell-free DNA analysis workflow alongside a cutting-edge mutation enrichment technology, ICE COLD PCR, that will enable laboratories to efficiently use these technologies to support liquid biopsy testing.
Read More
National Cancer Institute Grants Support Liquid Biopsy Studies
With three NCI grants, BioFluidica is investigating chip-based liquid biopsy technologies for the detection of cancer and related genetic variants.
Read More
Olympus Biopsy Needles Improve Staging of GI Disease
The 25-gauge biopsy needle completes the company’s product line, with expanded FDA indications for both fine needle aspiration and fine needle biopsy.
Read More
Palmetto GBA Issues Draft Local Coverage Determination for Decipher Prostate Biopsy Genomic Classifier
The draft LCD permits coverage for the use of Decipher among men with very low and low risk of prostate cancer according to National Comprehensive Cancer Network guidelines.
Read More